- Report
- February 2024
- 70 Pages
Japan
From €4249EUR$4,750USD£3,641GBP
- Report
- August 2023
- 75 Pages
North America
From €4249EUR$4,750USD£3,641GBP
- Report
- August 2023
- 70 Pages
Latin America
From €4249EUR$4,750USD£3,641GBP
- Report
- October 2022
- 70 Pages
Africa
From €4249EUR$4,750USD£3,641GBP
- Report
- May 2024
- 134 Pages
Global
From €2683EUR$2,999USD£2,299GBP
€3577EUR$3,999USD£3,065GBP
- Report
- July 2024
- 70 Pages
Brazil
From €4249EUR$4,750USD£3,641GBP
- Report
- May 2024
- 213 Pages
Global
From €4468EUR$4,995USD£3,828GBP
- Report
- September 2025
- 142 Pages
Global
From €3500EUR$4,191USD£3,104GBP
- Report
- September 2025
- 87 Pages
Global
From €3500EUR$4,191USD£3,104GBP
- Report
- May 2025
- 132 Pages
Global
From €4339EUR$4,850USD£3,717GBP
- Report
- January 2024
- 120 Pages
United States
€3131EUR$3,500USD£2,683GBP
Invokana is a prescription medication used to treat type 2 diabetes, a chronic endocrine and metabolic disorder. It belongs to a class of drugs known as sodium-glucose cotransporter-2 (SGLT2) inhibitors, which work by blocking the reabsorption of glucose by the kidneys, allowing it to be eliminated in the urine. Invokana is taken orally once a day and is typically used in combination with diet and exercise to improve glycemic control. It is also used to reduce the risk of cardiovascular events in adults with type 2 diabetes and established cardiovascular disease.
Invokana is marketed by Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson. Other companies in the market include AstraZeneca, Boehringer Ingelheim, Eli Lilly, Merck, Novo Nordisk, and Sanofi. Show Less Read more
